INVESTORS

SOLID SCIENCE - NEAR TERM  GROWTH OPPORTUNITY

​

Gene therapy is one of the hottest growth areas in biotech with more than $9 Billion invested in a2018, up 64% from 2017 and 2018.

​

Cellastra is targeting dermal scarring, a market expected to double to35 B USD by 2025.

​

CELLEXA Gene Therapy applied in the wound area switches on the pproduction of natural anti-scarring peptides already found to be safe and effective in clinical studies to date.

​

Rather than trying to apply topical treatment for weeks or months,one treatment with CELLEXA  turns on the cell factory in local cell of he targeted wound area to produce anti-scarring peptides for many weeks or months

​

See Investor Contacts: